Literature DB >> 11603882

Mechanisms of antipsychotic-induced weight gain.

R S McIntyre1, D A Mancini, V S Basile.   

Abstract

The estimated percentage of persons with schizophrenia who are overweight is higher than the percentage of persons in the general population who are overweight. The increased mortality rate for persons with schizophrenia is largely due to obesity-related diseases. The atypical antipsychotics offer an improved therapeutic index when compared with the conventional agents, but may impart serious adverse events such as weight gain. This brief review is intended to provide the practicing clinician with an update of disparate research paradigms under investigation in an attempt to delineate the biological mechanisms that presage weight gain. Research success in this area may invite novel prevention strategies and hint at potential mechanisms of antipsychotic drug action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11603882

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

Review 2.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

Review 4.  Genetic predictors of therapeutic response to clozapine: current status of research.

Authors:  Dalu Mancama; Maria J Arranz; Robert W Kerwin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Authors:  Josep Maria Haro; Luis Salvador-Carulla
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.

Authors:  Edward D Huey; Karen T Putnam; Jordan Grafman
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

7.  Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.

Authors:  Daniel E Casey; William H Carson; Anutosh R Saha; Amy Liebeskind; Mirza W Ali; Darlene Jody; Gary G Ingenito
Journal:  Psychopharmacology (Berl)       Date:  2003-02-28       Impact factor: 4.530

8.  The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.

Authors:  Martina von Wilmsdorff; Marie-Luise Bouvier; Uwe Henning; Andrea Schmitt; Wolfgang Gaebel
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

Authors:  Marilyn Ader; W Timothy Garvey; Lawrence S Phillips; Charles B Nemeroff; Georges Gharabawi; Ramy Mahmoud; Andrew Greenspan; Sally A Berry; Dominique L Musselman; Jacqueline Morein; Young Zhu; Lian Mao; Richard N Bergman
Journal:  J Psychiatr Res       Date:  2008-02-25       Impact factor: 4.791

10.  Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths.

Authors:  Gary S. Kabinoff; Patrick A. Toalson; Kristine Masur Healey; Hillary C. McGuire; Donald P. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.